Workflow
poziotinib
icon
Search documents
SPECTRUM FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors of the Class Action Lawsuit Filed Against Spectrum Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm Before September 24th
Globenewswire· 2025-09-23 22:19
Core Viewpoint - A class action lawsuit has been filed against Spectrum Pharmaceuticals, Inc. for allegedly making false and misleading statements regarding its Pinnacle Study of poziotinib for lung cancer treatment, which was less favorable than presented to investors [3][7]. Allegation Details - The lawsuit claims that Spectrum's public statements during the class period from March 17, 2022, to September 22, 2022, were false and materially misleading [3][7]. - The Pinnacle Study results were not as positive as the company portrayed, leading to investor losses [3]. Next Steps - Investors who purchased Spectrum shares during the class period and suffered losses are encouraged to contact the law firm Bragar Eagel & Squire for more information and to discuss their legal rights [4][7]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is September 24, 2025 [7]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in complex litigation across the United States [5].
Spectrum Pharmaceuticals (SPPI) and Assertio Holdings (ASRT) Investor Alert: FINAL DEADLINE in Securities Lawsuit– Hagens Berman
Globenewswire· 2025-09-23 20:37
SAN FRANCISCO, Sept. 23, 2025 (GLOBE NEWSWIRE) -- A New York federal court has re-opened the lead plaintiff process in the Spectrum Pharmaceuticals (SPPI) securities class action. This development offers a new opportunity for investors to represent the class after the previously appointed lead plaintiff was disqualified on August 4, 2025. The new deadline to apply is September 24, 2025. Importantly, (1) investors who purchased Spectrum (SPPI) common shares on the open market during the Class Period and (2) ...
CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Spectrum Pharmaceuticals (NASDAQ: SPPI) Investors to Inquire About a Securities Fraud Class Action by September 24, 2025
Prnewswire· 2025-09-23 12:36
Accessibility StatementSkip Navigation PHILADELPHIA, Sept. 23, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC is investigating securities fraud claims against Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) ("Spectrum" or the "Company") on behalf of investors who purchased or otherwise acquired common shares of Spectrum between March 17, 2022 through September 22, 2022(the "Class Period"). Investor Deadline: Investors who purchased or acquired Spectrum securities during the Class Pe ...
SPPI FINAL DEADLINE: ROSEN, TOP RANKED INVESTOR RIGHTS COUNSEL, Encourages Spectrum Pharmaceuticals, Inc. Investors to Secure Counsel Before Important September 24 Deadline in Securities Class Action – SPPI
Globenewswire· 2025-09-22 21:25
NEW YORK, Sept. 22, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) between May 12, 2022 and September 22, 2022, both dates inclusive (the “Class Period”), of the important September 24, 2025 lead plaintiff deadline. The lead plaintiff process was reopened by the Court. SO WHAT: If you purchased Spectrum Pharmaceuticals common stock during the Class Period you may be entitled to compensation ...
Spectrum Pharmaceuticals (SPPI) and Assertio Holdings (ASRT) Investor Alert: 3-DAY DEADLINE in Securities Lawsuit– Hagens Berman
Globenewswire· 2025-09-21 15:23
Core Viewpoint - A New York federal court has reopened the lead plaintiff process in the Spectrum Pharmaceuticals (SPPI) securities class action, allowing new investors to represent the class after the previous lead plaintiff was disqualified [1][4]. Group 1: Class Action Details - Investors who purchased Spectrum (SPPI) common shares during the Class Period (Mar. 17, 2022 – Sept. 22, 2022) and those who received shares of Assertio Holdings (ASRT) due to Assertio's acquisition of Spectrum may be eligible to represent the class [2][5]. - The federal class action, Christiansen v. Spectrum Pharmaceuticals, Inc., alleges that Spectrum misled investors about the success of its cancer treatment drug, poziotinib, leading to a share price drop of over 37% when FDA concerns were revealed [3][4]. Group 2: Legal Proceedings - The case has survived a motion to dismiss, and plaintiffs had moved for class certification, but proceedings were stayed due to allegations of misconduct by the court-appointed lead plaintiff [4]. - The new deadline for applying to be the lead plaintiff is September 24, 2025 [3]. Group 3: Hagens Berman's Role - Hagens Berman is actively investigating claims related to the case and encourages investors who suffered significant losses to consider becoming the new lead plaintiff [6]. - The firm has a history of representing investors and has secured over $2.9 billion in similar cases [7].
SPPI Deadline: SPPI Investors with Losses in Excess of $100K Have Opportunity to Lead Spectrum Pharmaceuticals, Inc. Securities Fraud Lawsuit
Prnewswire· 2025-09-20 18:00
Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Spectrum Pharmaceuticals, Inc. during the specified class period of the upcoming lead plaintiff deadline on September 24, 2025 [1]. Group 1: Class Action Details - Investors who bought Spectrum Pharmaceuticals common stock between May 12, 2022, and September 22, 2022, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][5]. - The lawsuit alleges that Spectrum made false or misleading statements regarding its PINNACLE Study related to the drug poziotinib, which impacted investors when the true details were revealed [5]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may not have the necessary experience or resources [4]. - The Rosen Law Firm has a history of successful settlements, including the largest securities class action settlement against a Chinese company at the time, and has recovered hundreds of millions for investors [4]. Group 3: Class Certification Status - No class has been certified yet, meaning investors are not represented by counsel unless they retain one, and they can choose to remain absent from the class [6].
SPPI DEADLINE NOTICE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Spectrum Pharmaceuticals, Inc. Investors to Secure Counsel Before Important September 24 Deadline in Securities Class Action – SPPI
Globenewswire· 2025-09-19 21:26
Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Spectrum Pharmaceuticals, Inc. during the specified Class Period of the upcoming lead plaintiff deadline on September 24, 2025, as the lead plaintiff process has been reopened by the Court [1]. Group 1: Class Action Details - Investors who bought Spectrum Pharmaceuticals common stock between May 12, 2022, and September 22, 2022, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed against Spectrum Pharmaceuticals, and interested parties can join by contacting the law firm [3][5]. - The lawsuit alleges that Spectrum made false or misleading statements regarding its PINNACLE Study, which involved the drug poziotinib for lung cancer treatment, leading to investor damages when the truth was revealed [5]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may not have the necessary experience or resources [4]. - The Rosen Law Firm has a history of successful settlements in securities class actions, including a record settlement against a Chinese company and significant recoveries for investors in previous years [4]. Group 3: Class Certification Status - No class has been certified yet, meaning investors are not represented by counsel unless they retain one, and they can choose to remain absent from the class [6].
SPECTRUM DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors of the Class Action Lawsuit Filed Against Spectrum Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm Before September 24th
Globenewswire· 2025-09-19 14:41
Group 1 - A class action lawsuit has been filed against Spectrum Pharmaceuticals, Inc. for allegedly making false and misleading statements regarding its Pinnacle Study of poziotinib for lung cancer treatment [3][7] - The lawsuit covers all individuals and entities who purchased or acquired Spectrum securities between March 17, 2022, and September 22, 2022, inclusive [7] - Investors have until September 24, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit [7] Group 2 - The law firm Bragar Eagel & Squire, P.C. is representing the investors in this class action and encourages those who suffered losses to contact them for more information [4][5] - The firm specializes in representing individual and institutional investors in various types of litigation across state and federal courts [5]
Spectrum Pharmaceuticals (SPPI) and Assertio Holdings (ASRT) Investor Alert: 6-DAY DEADLINE in Securities Lawsuit – Hagens Berman
Globenewswire· 2025-09-19 13:50
Group 1 - A New York federal court has re-opened the lead plaintiff process in the Spectrum Pharmaceuticals (SPPI) securities class action, allowing new investors to apply by September 24, 2025 [1][2] - The class period for the lawsuit is from March 17, 2022, to September 22, 2022, and the case has survived a motion to dismiss [3][4] - The lawsuit alleges that Spectrum misled investors about the success of its cancer treatment drug, poziotinib, leading to a share price drop of over 37% when FDA concerns were revealed [3][4] Group 2 - Assertio Holdings (ASRT) acquired Spectrum Pharmaceuticals in July 2023, allowing investors who received ASRT shares after acquiring SPPI shares during the class period to potentially represent the class [5] - Hagens Berman is encouraging investors who suffered significant losses to consider becoming the new lead plaintiff, emphasizing the importance of this role in overseeing litigation [6]
DEADLINE NEXT WEEK: Berger Montague Advises Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) Investors to Contact the Firm Before September 24, 2025
Globenewswire· 2025-09-18 21:06
Core Viewpoint - National plaintiffs' law firm Berger Montague PC is investigating securities fraud claims against Spectrum Pharmaceuticals, Inc. for misleading statements made during the Class Period from March 17, 2022, to September 22, 2022 [1][3] Company Overview - Spectrum Pharmaceuticals is a biopharmaceutical company focused on oncology treatments [2] Legal Proceedings - A class action lawsuit has been filed alleging that Spectrum made false or misleading statements regarding its Pinnacle Study, which involved the drug poziotinib for lung cancer treatment [3] - Investors who acquired Spectrum securities during the Class Period have until September 24, 2025, to seek appointment as lead plaintiff representative [2] Contact Information - Investors seeking more information can contact Andrew Abramowitz or Caitlin Adorni at Berger Montague [4][6]